Clinical trials: Gefitinib
Non Small Cell Lung Cancer
GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
A sub-population of patients affected by non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) do not gain benefit from treatment with tyrosine-kinase inhibitors (TKIs).
- Trial name
- NCT02319577
- Testing
- oral vinorelbine, Gefitinib
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
EGFR Mutation Positive Non-small Cell Lung Cancer
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
- Trial name
- NCT01776684
- Testing
- EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Non Small Cell Lung Cancer (NSCLC)
Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of…
- Trial name
- NCT00683306
- Testing
- ZD1839 (Iressa)
- Where
- 65 sites in Argentina, Australia and 17 more
- Sponsor
- AstraZeneca
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Lung Cancer
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
- Trial name
- NCT00238628
- Testing
- Bexarotene, Iressa
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Pancreatic Cancer
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
The primary objective of the trial is to identify the dose of gemcitabine given as a 2-hour intravenous (iv) infusion that can be administered in combination with ZD1839 250 mg once daily and a standard course (45 Grays [Gy]) of…
- Trial name
- NCT00234416
- Testing
- Gefitinib, Gemcitabine
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Lung Cancer, Breast Cancer
Iressa Follow-up Trial
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).
- Trial name
- NCT00357734
- Testing
- Gefitinib
- Where
- 7 sites in Germany
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
This randomized phase II trial studies how well pemetrexed disodium and carboplatin or cisplatin with or without erlotinib hydrochloride work in treating patients with epidermal growth factor receptor (EGFR) mutant positive stage…
- Trial name
- NCT01928160
- Testing
- pemetrexed disodium, carboplatin, cisplatin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Liver Cancer
Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
This research is being done to find how soon the liver cancer may come back and whether proteins or genes in tumor, blood or urine can give us clues of early recurrence.
- Trial name
- NCT00282100
- Testing
- Gefetinib (Iressa)
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Tan Tock Seng Hospital
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Rare Tumor, Refractory Tumor
Efficacy and Safety of Precision Therapy in Refractory Tumor
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.
- Trial name
- NCT03239015
- Testing
- Gefitinib, Erlotinib, Afatinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Baodong Qin
Esophageal Cancer
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00493025
- Testing
- cisplatin, gefitinib, paclitaxel
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Small Cell Lung Cancer, EGFR Gene Mutation
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation
- Trial name
- PIKACHU (NCT04322890)
- Testing
- Osimertinib, Alectinib 150 MG, Crizotinib 250 MG
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Hunan Province Tumor Hospital
Stage IV Non-small Cell Lung Cancer
Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer
This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth…
- Trial name
- NCT03595644
- Testing
- SBRT+TKI, TKI
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tongji Hospital
Carcinoma, Non-Small-Cell Lung
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer). Patients will be recruited from participating sites in Europe, Asia, and Canada.
- Trial name
- PANORAMA (NCT03053297)
- Testing
- Patient Reported Outcomes
- Where
- 110 sites in Canada, China and 4 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
The aim of the study is to determine if Iressa added to chemotherapy with Irinotecan, 5Fluorouracil and Leucovorin can prolong the period of time without any disease worsening (Time to Progression) in patients with metastatic…
- Trial name
- NCT00233623
- Testing
- Iressa (Gefitinib), Irinotecan, 5Fluorouracil
- Where
- 13 sites in Italy
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Refractory Germ Cell Tumors Expressing EGRF
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to withdraw.
- Trial name
- IUCRO-0021 (NCT00198159)
- Testing
- ZD1839 Iressa
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Indiana University
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Brain Metastasis
Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of gefitinib in patients with asymptomatic advanced NSCLC who was benefitted by first line chemotherapy.
- Trial name
- NCT00614809
- Testing
- gefitinib
- Volunteers
- 45 people
- Sponsor
- Guangdong Provincial People's Hospital
Stage IV EGFR Mutated NSCL With Brain Metastases
Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
A multi-center phase III randomized controlled study to evaluate the efficacy of Hypofractionated SRS (HFSRS) along with EGFR-TKI in patients with brain metastasis from non-small cell lung cancer (NSCLC).
- Trial name
- Hybrid (NCT02882984)
- Testing
- Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib, WBRT, HFSRS
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Sichuan Provincial People's Hospital